Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.35 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.35 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.35 |
| ▸ | XDH | P47989 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4062168 | 0.81 | ALDH1A1 (0.60) | SMN1; SMN2ALDH1A1HPGDKDM4EGAA | |
| SCHEMBL4062163 | 0.76 | SMN1; SMN2 (0.54) | SMN1; SMN2ALDH1A1HPGDXDHTP53 | |
| SCHEMBL7495317 | 0.76 | ADORA1 (0.39) | SMN1; SMN2ALDH1A1HPGDGAAGABRA1 | |
| SCHEMBL14511042 | 0.73 | XDH (0.56) | SMN1; SMN2ALDH1A1HPGDXDHPOLB | |
| SCHEMBL9451696 | 0.73 | SMN1; SMN2 (0.50) | SMN1; SMN2ALDH1A1HPGDKDM4EGAA | |
| SCHEMBL4063853 | 0.73 | ALDH1A1 (0.50) | SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL9838320 | 0.69 | KDM4E (0.58) | SMN1; SMN2ALDH1A1HPGDKDM4EGAA | |
| SCHEMBL311846 | 0.68 | ALDH1A1 (0.49) | SMN1; SMN2ALDH1A1HPGDKDM4EGDA | |
| SCHEMBL12820930 | 0.68 | ALDH1A1 (0.55) | SMN1; SMN2ALDH1A1HPGDKDM4EGAA | |
| SCHEMBL15290198 | 0.68 | SMN1; SMN2 (0.49) | SMN1; SMN2ALDH1A1HPGDKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062316-A1 | DEUTERIUM-ENRICHED PELITREXOL | PROTIA, LLC (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090062316-A1 | DEUTERIUM-ENRICHED PELITREXOL | PROTIA, LLC (US) | 2009-03-05 | — | — | US | disclosed |
| EP-1482977-A1 | COMBINATION THERAPIES FOR TREATING METHYLTHIOADENOSINE PHOSPHORYLASE DEFICIENT CELLS | PFIZER INC. (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20040043959-A1 | Combination therapies for treating methylthioadenosine phosphorylase deficient cells | AGOURON PHARMACEUTICALS INC. | 2004-03-04 | — | — | US | disclosed |
| WO-2003074083-A1 | COMBINATION THERAPIES FOR TREATING METHYLTHIOADENOSINE PHOSPHORYLASE DEFICIENT CELLS | PFIZER INC. (US) | 2003-09-12 | — | — | WO | disclosed |
| EP-0773943-B1 | COMPOUNDS USEFUL AS ANTIPROLIFERATIVE AGENTS AND GARFT INHIBITORS | AGOURON PHARMA (US) | 2001-09-26 | — | — | EP | disclosed |
| US-5646141-A | THIENYLALKYLATED DERIVATIVES OF PYRIDO(2,3-D)-PYRIMIDINE, PYRIMIDO(5,4-6)-(1,4)THIAZINE OR PYRIMIDO(5,4-6)-(1,4)SELENAZINE | AGOURON PHARMACEUTICALS, INC. (US) | 1997-07-08 | — | — | US | disclosed |
| US-5608082-A | GARFT = THE ENZYME GLYCINAMIDE RIBONUCLEOTIDE FORMYL TRANSFERASE | AGOURON PHARMACEUTICALS, INC. (US) | 1997-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062316-A1 | DEUTERIUM-ENRICHED PELITREXOL | CYP24A1, CYP2R1, CYP27B1 | SMN1; SMN2 4290/4885ALDH1A1 2243/4885HPGD 112/4885 |
| US-20040043959-A1 | Combination therapies for treating methylthioadenosine phosphorylase deficient cells | APRT, MTAP, TYMP | SMN1; SMN2 1993/4885ALDH1A1 975/4885HPGD 2966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.